Michael Cherny
Stock Analyst at B of A Securities
(4.01)
# 582
Out of 5,005 analysts
118
Total ratings
55.56%
Success rate
10.81%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $785 → $850 | $738.06 | +15.17% | 15 | Sep 24, 2025 | |
| PINC Premier | Maintains: Underperform | $19 → $21 | $27.90 | -24.72% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $154.46 | +20.42% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $20.59 | +35.99% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.23 | +143.90% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.85 | +10.31% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $532.49 | -38.03% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $52.54 | -23.87% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $77.49 | -3.21% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $73.26 | +22.85% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $132.17 | +111.85% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $179.33 | -2.97% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $67.03 | +25.32% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $206.63 | +20.02% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $193.89 | +31.52% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.19 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $302.76 | -9.17% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $276.94 | -6.12% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.53 | +76.60% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $13.07 | +45.37% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $9.01 | +88.68% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $4.72 | +1,012.29% | 2 | Jan 5, 2022 |
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $738.06
Upside: +15.17%
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $27.90
Upside: -24.72%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $154.46
Upside: +20.42%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $20.59
Upside: +35.99%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.23
Upside: +143.90%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.85
Upside: +10.31%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $532.49
Upside: -38.03%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $52.54
Upside: -23.87%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $77.49
Upside: -3.21%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $73.26
Upside: +22.85%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $132.17
Upside: +111.85%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $179.33
Upside: -2.97%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $67.03
Upside: +25.32%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $206.63
Upside: +20.02%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $193.89
Upside: +31.52%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.19
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $302.76
Upside: -9.17%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $276.94
Upside: -6.12%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.53
Upside: +76.60%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $13.07
Upside: +45.37%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $9.01
Upside: +88.68%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $4.72
Upside: +1,012.29%